Primary To determine the tolerability and identify the recommended Phase 2 combination dose (RP2CD) of lazertinib when combined with JNJ-61186372 (Phase 1b combination cohorts)
What is the full name of this clinical trial?
73841937NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 , a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer